Earnings Call · Q4 FY2022·2023-02-28

Q4 22EPS +8.89%·Rev n/aQ3 22EPS +77.27%·Rev n/aQ2 22EPS +22.45%·Rev n/aQ1 22EPS +12.07%·Rev n/a⚠ consensus missing

Atea Pharmaceuticals, Inc. AVIR

Jonae Barnes — Investor Relations or Corporate Communications

Jean Sommadossi — Chief Executive Officer

Andrea Corcoran — Chief Financial Officer

−8.2%1d on move date−7.8% vs SPY3d−0.3%5d−5.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AVIR calls or request research access.

More AVIR calls Browse calls Request research access